Step 3: Regulatory review.

Regulatory review is the stage where we confirm that the specific drug-indication-destination combination can actually move through a named-patient pathway in the country where the patient resides, and that the paperwork required by that pathway will be in order before a unit ships. Named-patient programs differ materially across the countries we serve; a pathway that is straightforward for one therapy into the United Arab Emirates may require different documentation for the same therapy into Saudi Arabia, and an indication that is well-trodden in India may need a fresh application in Egypt. Regulatory review exists to resolve all of that before any product moves.

What regulatory review checks

The AI Regulatory Review Agent maintains a jurisdictional map of named-patient pathways across the countries we operate into and performs a structured check on three questions. The first is pathway availability: does the destination country recognize a named-patient or compassionate-use pathway for this drug-indication combination, and under what conditions. The second is documentation requirements: what specific documents will the destination regulator expect, in what language, under what signatures, and at what timing relative to shipment. The third is operational feasibility: given the pathway and the documentation requirements, can we execute on a timeline that matches the clinical urgency of the case.

Jurisdictional sign-off

The AI Regulatory Review Agent produces a structured recommendation; a human regulatory advisor reviews that recommendation and signs off on the pathway choice and the documentation package before we proceed. For destinations and indications we have run many times, the human review is quick and largely confirmatory; for destinations and indications we are running for the first time, or where the regulatory environment has moved recently, the human review may include a direct inquiry to the destination regulator or to a local counsel partner. We do not guess on regulatory questions; we either know, or we confirm, or we hold the case and say so.

Pathway selection

Named-patient pathways take different shapes in different countries. Some destinations operate a formal named-patient import authorization issued case-by-case by the health authority. Some operate a compassionate-use pathway that requires a physician affidavit and a patient consent but no pre-authorization. Some require the therapy to be unavailable locally, a determination that must be documented. Some require the prescriber to hold a specific license for the therapy class. The pathway we select is the one that best fits the case on legal, timeline, and documentation grounds, and we explain the choice to the prescriber so they understand what their role will be.

Paperwork package

The paperwork we assemble for a typical named-patient case includes the prescription, the medical-necessity letter, the patient consent, the physician's licensing evidence where the destination requires it, the import-authorization application or equivalent, the manufacturer's product documentation, and the shipping manifest keyed to the DSCSA transaction records the product will ship with. Where the destination country expects documents in a local language, we coordinate certified translation through a qualified translation partner. Where the destination expects notarization or apostille, we coordinate that through our licensed broker at destination. The package is assembled, reviewed for internal consistency, and filed according to the destination's process before the unit is released for shipment.

When regulatory review leads to a decline

Regulatory review produces a decline when the named-patient pathway is closed for the indication in question, when the timeline of the pathway is incompatible with the clinical urgency, or when a documentation requirement cannot be met with the materials available. When we decline on regulatory grounds, we explain precisely what we saw and, where possible, point the prescriber toward an alternative pathway. For destinations where the named-patient pathway is closed but the manufacturer operates a separate global-access program, we suggest that pathway; where the timeline is the problem, we describe the time-course realistically so the prescriber can make an informed clinical decision about whether to wait or to consider an alternative therapy.

Ongoing regulatory monitoring

Named-patient regimes in the countries we serve change. Some changes tighten the pathway; some loosen it. Our AI Regulatory Review Agent maintains an ongoing monitor of regulatory gazettes, ministry of health announcements, and pharmacy regulator notices across our coverage map, and our human advisors review those changes on a weekly cadence. When a change materially affects an open case, we notify the prescriber and adjust the pathway; when a change expands what we can do, we update the coverage map and the published guidance.

Handoff to sourcing

Once regulatory review has issued a positive determination and the paperwork package is ready to file, the case moves to sourcing and logistics. From this point forward, the clinical and regulatory reviews remain available as references; if a new fact emerges mid-case that warrants re-review, we pause sourcing and re-review rather than push a case past a concern that emerged late.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.